Company Performance Metrics
- Sam Merchant: Co-Founder and Executive Chairman Of The Board
- Cheryl Baker: Director, Co-Founder and Chief Scientific Research Officer
BioCurity Pharmaceuticals is a biopharmaceutical company with a mission to transform a cancer patient’s recovery, by addressing a global unmet need for an effective treatment to mitigate radiation therapy toxicity. It is on track to fundamentally change the course of radiation therapy for cancer patients, worldwide.
Approximately 6 million of the
18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world.
BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity, not just for newly diagnosed patients, but also for the millions of patients who must receive radiation as a part of their ongoing treatment for cancer.
